Gem Aromatics Q2 FY26 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- GEM Aromatics anticipates revenue growth from new customers, especially in the Cooling Agents segment, starting from Q4 FY '26 and continuing into FY '27.
- The company aims to reduce dependence on the Mint portfolio (which was 70% of revenue in FY '25) by fast-tracking value-added specialty products and aroma chemicals targeted at domestic and export markets.
- Production of Cooling Agents is set to commence by November 30, 2025, with reasonable utilization expected from December onwards, leading to topline growth in that category in FY '27.
- The newly set up multipurpose plant (Phase-II) for Phenol derivatives will become operational by early FY '27, contributing to capacity and product diversity.
- GEM Aromatics expects a normalized demand recovery and stabilization by Q4 FY '26 as external tariff and GST-related issues subside.
- The company targets operating EBITDA margins of 16%-18% by FY '28 with scaled revenues from new product lines and operational efficiency improvements.
See what Gem Aromatics management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no explicit mention of any current or planned new fundraising through debt or equity in the Q2 FY '26 conference call.
- The company recently completed an IPO (listing on NSE and BSE on August 26), which was used to strengthen the balance sheet and partly repay borrowings.
- Significant repayment of Rs. 140 crores debt was made, improving the net debt to equity ratio from 0.8x to 0.3x, indicating a focus on deleveraging rather than new borrowing.
- The management has not announced any new capital raising plans during this call.
- Focus appears to be on utilizing existing resources for ongoing CAPEX and growth initiatives, with no indication of fresh equity or debt funding in the near term.
See what Gem Aromatics management said on order book — free account, 30 seconds.
Capex plans
Yes- GEM Aromatics is investing in a multi-purpose plant, with Phase-II (primarily for Phenol derivatives such as MEHQ and Guaiacol) becoming operational by November 30, 2025, with production starting around January/February 2026.
- The company is adding a capacity of around 10,829 MTPA focusing largely on Phenol derivatives.
- The Cooling Agent production is set to commence by November 30, 2025, with reasonable utilization expected from December 2025 and normalization in FY '27.
- The company is fast-tracking the launch of value-added specialty aroma chemical products, originally planned for FY '27 and FY '28, to mitigate current market headwinds.
- GEM Aromatics aims for consolidated EBITDA of Rs. 1,050-Rs. 1,100 crores with margins of 16%-18% by FY '28 driven by these expansions.
- IPO proceeds have been used for partial repayment of borrowings to strengthen the balance sheet and support growth investments.
Track Gem Aromatics — get its next earnings analysis in your feed
Margin guidance
Category 3- GEM Aromatics aims for EBITDA of Rs. 1,050-Rs. 1,100 crores by FY '28 with margins of 16%-18%.
- The company plans to reduce dependence on Mint and Mint derivatives by ramping up value-added specialty aroma chemical products starting FY '27.
- Production of Cooling Agents to commence by November 30, 2025, with topline contribution expected from Q4 FY '26 and normalized capacity utilization in FY '27.
- Fast-tracking new product launches (e.g., Phenol derivatives like BHA) to replace Mint segment revenues and improve margins.
- Management expects stabilization of the current demand blip by Q4 FY '26, leading to normalization and growth.
- Focus on technology-driven innovation, import substitution, and sustainability to drive long-term profitable growth.
- Gross margins expected to recover to long-term averages once external pressures (GST, tariffs) subside.
Order book
How does Gem Aromatics rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Gem Aromatics rank in Chemicals & Petrochemicals?
Compare Gem Aromatics against every Chemicals & Petrochemicals company (Q2 FY26) on revenue, margins and earnings-call signals.
Continue your research
What Gem Aromatics's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Sudarshan Chemical Industries Ltd (Q1 FY27)
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
- Indo Borax & Ch. (Q1 FY27)
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
- SRF (Q1 FY27)
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…
- Deepak Fertilis. (Q1 FY27)
Long-term demand-supply balance looks stable with 6-7% market growth, supporting sustained revenues despite new capacity additions. Key concall takeaways from…